Recently, multiple prescription drugs have received accelerated or full FDA approval for adults with kidney disease to delay progression, with a few such as sparsentan, a dual endothelin and angiotensin II receptor antagonist, iptacopan an alternative complement factor B inhibitor, and an oral targeted release formulation of budesonide recently coming to market for IgAN [30–33]. The gene discussed is CFB; the disease is kidney disorder.